To account for severity of disease in patients with erectile dysfunction, we introduced a progressive treatment technique using four protocols of drug injections.
Introduction
In 1982 Virag 1 introduced the use of intracorporeal injections of papaverine hydrochloride for the diagnosis and treatment of erectile dysfunction (ED). One year later Brindley 2 published his results with intracavernosal injections of phentolamine, and thereafter the effectiveness of the combination of papaverine and phentolamine was described by several authors. 3 ± 6 Over the next decade, prostaglandin E 1 7 ± 11 was added to this regimen 12 ± 15 followed by a fourth agent, atropine sulfate. 16 The common feature of all these agents is their vasodilatative effect. They act on the smooth muscle of blood vessels by different mechanisms. Papaverine has a direct smooth muscle relaxant action. Phentolamine produces a competitive block of a-1 and a-2 receptors in smooth muscle. Prostaglandin affects the smooth muscle by chemical reactions. Atropine acts by inhibiting the muscarinic action of acethylcholine in postganglionic synapses.
Despite the many studies on vasoactive agents, only a few have involved wide series of patients, and little has been reported on the follow-up of the failures. To the best of our knowledge, no investigations have been conducted comparing different combinations or dosages of these four agents.
To account for the different degrees of severity in ED, and to offer patients optimal treatment, we introduced a progressive, four-protocol technique of drug injections. The immediate and follow-up results are reported.
Materials and methods

Patients
The study group consisted of 452 men aged 26 ± 85 y (mean, 59.5 AE 4.5 y) with ED. Diagnosis of ED was based on anamnestic data of the patient and his female partner, physical examination, penile brachial index (PBI), nocturnal penile tumescence (NPT) (Rigiscan), blood tests for glucose loading, testosterone and prolactin, penile Doppler stethoscopy and duplex ultrasonography.
Marital status
Three hundred and ninety-two patients (86.7%) were married, 6 (1.3%) were single, 26 were widowed (5.7%) and 28 were divorced (6.1%).
Other disorders
Ninety-four percent had been treated with more than two drugs for a variety of chronic diseases; 39.3% had undergone surgery which may have affected erection.
Previous treatment for ED
Three hundred and seventy-three patients (82.5%) had received medications, vacuum therapy and psychotherapy, and 82 (18.2%) had had intracorporeal injections of vasoactive agents.
Type of dysfunction
Organic 311 patients (68.8%), psychogenic 21 (4.6%), mixed etiology 120 (26.5%).
Method
Before initiation of treatment, the patients, alone or with their partners, received an explanation of the mechanism of action of the vasoactive agents, their side effects and complications and instructions on what to do in the event of complications and side effects, especially priapism. Printed instructions were also handed out. All patients signed an informed consent form prior to onset of the trial.
Patients were asked to empty their bladder before every injection and to avoid urination for 1 ± 3 h after the injection. Emptying the urinary bladder decreases the rigidity of the penis, and this helps us to determine the exact dose and combination of vasoactive drugs.
The treatment was divided into four protocols.
Protocol I
All patients in the study received Protocol I, which consisted of three injections, one week apart, of papaverine 6 ± 25 mg and Regitine (phentolamine) 0.05 ± 1.5 mg. The initial dose was determined individually by age, physical condition, anamnestic data and type of dysfunction. After the injection the patient was asked to wait for 5 ± 30 min, and then his erection was evaluated. Maximal rigidity of the penis (MRP) was evaluated according to the angle between the body and the penis ( Figure 1) . A MRP b 80% was considered a positive response, suf®cient for penetration (angle between body and penis, 80 ± 90 ). MRP`80% was considered a negative response, insuf®cient for penetration (angle between body and penis 95 ±110
). At the second session, one week later, individual doses were corrected and the quality and duration of the erection was assessed and the possibility of intercourse determined. This was repeated at the third visit. Patients with a MRP b 80% were taught to autoinject and were given ®ve to ten doses for self-treatment at intervals of four to six days.
Protocol II
Patients who failed to reach a MRP`80% with the maximal dose of papaverine and Regitine were put on Protocol II which consisted of prostin VR 10 ± 25 mcg (prostaglandin E1). Those who achieved a MRP b 80% after three sessions received ®ve to six doses for autoinjection at home.
Protocol III
Patients who failed Protocol II with the maximal dose of prostin VR were given a combination of papaverine 18 ± 25 mg, Regitine 1.0 ± 1.5 mg and prostin VR 10 ± 25 mcg.
Protocol IV
If the maximal dose of the trimix failed, patients were given four agents: (1) papaverine 20 ± 25 mg; (2) Regitine 1 ± 1.5 mg; (3) prostin VR 20 ± 25 mcg; and (4) atropine sulfate 0.02 ± 0.06 mg.
Patients who failed Protocol IV (two sessions) were offered a penile prosthesis.
All patients who achieved a MRP b 80% under any of the protocols were subjectively and objectively reevaluated after 40 ± 45 d for quality of erection. Physical examination was performed to Progressive treatment of erectile dysfunction J Shumeli et al identify ®brotic nodules and to determine PBI and NPT. Thereafter, patients received an additional 8 ± 12 injections and were asked to attend the outpatient clinic 2.5 ± 3 months later. Follow-up in all cases lasted six months or more. The results were statistically evaluated according to Bland. 17 Statistical signi®cance was considered when P`0.05.
Results
Protocol I
All 452 patients were given a combination of papaverine and Regitine. A MRP b 80% (suf®cient for penetration) was achieved after one injection in 32.1% and after two injections in 24.7%; the total positive response rate after three injections was 67.5% (305 patients) (Figure 2 Papaverine and Regitine were found to be effective in patients with idiopathic ED and ED due to familial disharmony, and in patients on dialysis, with hypertension, and with benign prostatic hypertrophy (BPH).
Protocol II
Of the 147 patients (32.5%) who failed Protocol I, 44 (29.9%) reached satisfactory erection after the ®rst injection on Protocol II and 17 patients (11.6%) after the second injection; the total positive response rate was 61 (41.4%). Prostin VR proved to be effective in patients with diabetes, hypertension and cardiovascular disease.
Protocol III
Of the 86 patients (58.5%) who failed Protocol II, 32 (37.2%) had positive results with the ®rst injection on Protocol III and 23 (26.7%) with the second injection; the total positive response rate was 55 (63.9%). This protocol proved to be effective in patients with BPH, diabetes, hypertension, and simple prostatectomy.
Protocol IV
Thirty-one patients (36.1%) who failed Protocol III were given Protocol IV. After two injections, 20 patients (64.5%) reached a MRP b 80%. Protocol IV was effective in patients after radical prostatectomy and patients with post-pelvic trauma, cardiovascular disease, and colonectomy.
Eleven patients (2.4%) failed all four protocols and were offered penile prosthesis. These included six (54.5%) after radical prostatectomy, one after heart transplant, and four with cardiovascular disease and diabetes and after transvesical prostatectomy. 
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Follow-up (six months)
The patients were evaluated by type of ED. We found that 296 patients had organic ED (out of 311 of the entire cohort) (95.1%), 21 psychogenic ED (100%), and 43 mixed ED (out of entire cohort of 120) (94.1%).
Of the 441 patients who had achieved a MRP b 80% on any of the protocols, 115 patients reported having coitus without injections at the sixmonth follow-up. These included 88 of the 311 patients with organic ED (28.2%), 15 of the 21 with psychogenic ED (71.4%), and 12 of the 120 with mixed ED (10%). Fifty-six (12.6%) stopped injections because of failure and 270 (61.2%) had successful coitus with injections.
Marital status apparently played a role in the success rate as well. Coitus without injection was achieved in 97 of the 392 married patients (24.7%) compared with only one of the six single patients (16.6%), three of the 28 divorced patients (10.7%), and six of the 14 widowers (53.8%).
PBI and NPT
The rate of patients with PBI b 0.75 increased from 25.4 AE 2.6% before treatment to 61.4 AE 4.2% six months after (P`0.001) in Protocol I patients (n 305); from 20.6 AE 2.9% to 49.6 AE 2.4% (P0 .001) in Protocol II patients (n 147); from 16.4 AE 3.4% to 22.6 AE 3.1 (P`0.01) in Protocol III patients (n 86). Of the patients on Protocol IV, PBI was 0.6 in 78.6 AE 5.4% before treatment and 72.2 AE 4.6% after treatment (P`0.5). For the groups as a whole, the rate of PBI b 0.75 rose from 24.2 AE 1.4% of patients before treatment to 71.2 AE 4.2% after treatment (at six months) (P`0.001).
The rate of patients with a slightly impaired NPT increased from 17.8 AE 1.6% to 49.5 AE 2.4% (P0 .001) after six months.
Complications and side effects
Of the 452 patients on Protocol I (305 MRP b 80%), 9 (1.9%) had priapism, 8 (1.7%) subcutaneous hemorrhage, 3 (0.6%) small nodules; of the 147 on Protocol II, 45 (30.6%) had pain, 5 (3.4%) priapism, 11 (7.4%) subcutaneous hemorrhage and 3 (2%) small nodules; of the 86 on Protocol III, 2 (2.3%) had pain, 4 (4.6%) subcutaneous hemorrhage, 3 (3.4%) small nodules; of the 31 patients on Protocol IV, 2 (6.4%) had pain, 8 (25.8%) subcutaneous hemorrhage and 3 (9.6%) small nodules. We found that before treatment PBI b 0.75 was found in 25.4 AE 2.6% of the patients and six months after treatment (61.4 AE 4.2%) with intracavernous injection (P`0.001). There was a correlation between PBI, NPT, general health of the patient and patient age: 90.2% of the patients with a negative NPT had a PBI`0.6, and 85.4% of these patients were over 65 y of age. These patients had undergone different surgical interventions and had been getting various drug treatments. Of the 115 patients with a positive NPT, 95 (82.6%) had a PBI b 0.75, 104 (90.4%) had a MRP b 80% and 85 (73.9%) were under 65 y old. Twenty-six (22.6%) had been receiving various drug treatments.
Discussion
There are many studies discussing the advantages, side effects and complications of vasodilatative agents, individually or in various combinations. 18 ± 21 Based on their ®ndings, we concluded that a compound of papaverine Regitine prostaglandin E-1 yields more effective results than papaverine Regitine or prostaglandin E-1 alone. 11, 14, 21, 22 In this present work, we attempted the gradual treatment of patients with ED, beginning with a dual combination of papaverine Regitine, because this is much less expensive than the three-drug protocol and easily available. In addition, prostaglandin E-1 causes pain of different intensities in 11.7 ±83.3% of patients. 23 ± 28 Those who failed to show a suf®cient erection (n 147) were then given Prostin only, and the remaining failures were given all three drugs (papaverine Regitine prostin). For patients who failed the trimix, we used papaverine Regitine prostin atropine. We did not recommend the use of Protocol IV from the beginning, because Montorsi et al, 16 who did so, reported many side effects, such as hematomas (25%), small nodules (5.3%), dizziness, and hypotension (6.3%). The results here were very similarÐsubcutaneous hemorrhage in 25.8% of Protocol IV patients and small nodules in 9.6%. Side effects with Protocols I, II and III were much rarer.
Both papaverine and atropine are effective vasodilators. Papaverine has a direct smooth muscle action, whereas atropine is a belladonna alkaloid which inhibits the muscarinic action of acethylcholine in postganglionic cholinergic nerves and smooth muscle. Their combination has long been popular in medicine. 29 When atropine was added to the regimen after failure of Protocol III, 64.5% of the patients responded. We did not use Protocol IV to begin with because Montorsi et al, 16 who did so, reported many side effects, such as hematomas (25%), small nodules (5.3%), and dizziness and hypotension (6.3%). Our results were similarÐ subcutaneous hemorrhage in 25.8% and small 
